Pharmaceutical Preparations · DE · CIK 1434647
Zevra Therapeutics develops and commercializes life-changing therapies for rare diseases
Comparable business profile · signals at a glance
In the 90 days to Feb 9, 2026: 5 sold $1.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Mcfarlane Neil F.President and CEO | Sell | 14,625 | $8.56 | $125K |
| Feb 3, 2026 | Schafer JoshuaCCO | Sell | 10,500 | $9.19 | $96K |
| Feb 3, 2026 | Sangiovanni Timothy J.SVP, Finance & Corp Controller | Sell | 3,000 | $9.18 | $28K |
| Feb 2, 2026 | Mcfarlane Neil F.President and CEO | Sell | 91,000 | $9.38 | $854K |
| Jan 30, 2026 | Quartel Adrian WChief Medical Officer | Sell | 4,533 | $8.83 | $40K |
| Jan 30, 2026 | Thompson RahsaanChief Legal & Compliance | Sell | 4,080 | $8.83 | $36K |
| Jan 30, 2026 | Schafer JoshuaCCO | Sell | 3,375 | $8.83 | $30K |
| Jan 30, 2026 | Sangiovanni Timothy J.SVP, Finance & Corp Controller | Sell | 1,750 | $8.82 | $15K |
| Oct 10, 2025 | Mcfarlane Neil F.President and CEO | Sell | 19,500 | $10.82 | $211K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.